Diffuse Large B-Cell Lymphoma Clinical Trails, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceu

DelveInsight's, "Diffuse Large B-Cell Lymphoma - Pipeline Insight, 2025," report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Diffuse Large B-Cell Lymphoma Pipeline constitutes 70+ key companies continuously working towards developing 75+ Diffuse Large B-Cell Lymphoma treatment therapies, analyzes DelveInsight.

Diffuse Large B-Cell Lymphoma Overview:

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma, accounting for approximately 25% to 30% of all cases. It typically manifests as rapidly enlarging lymph nodes or masses, which may occur within or outside the lymphatic system. DLBCL originates from abnormal B-cell proliferation, often stemming from germinal center B cells. Its development can be influenced by genetic mutations, immune system deficiencies, and infections such as the Epstein-Barr virus. DLBCL is a biologically diverse disease, with several molecular subtypes identified through gene expression profiling. The underlying pathophysiology often involves abnormalities in key genes such as BCL2, BCL6, and MYC. Standard treatment usually includes immunochemotherapy regimens like R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), and therapeutic strategies are often adapted based on disease stage and molecular subtype. Although DLBCL is aggressive, many patients achieve long-term remission with timely and effective treatment, underscoring the importance of early detection and personalized care.

Symptoms of DLBCL can vary widely but commonly include rapidly growing nodal or extranodal masses. Around 30% of patients present with B symptoms-fever, night sweats, and unintentional weight loss-linked to elevated cytokine levels. Bone marrow involvement is observed in up to half of the cases, while extranodal disease is present in approximately 50% of patients. Symptoms may also arise from tumor-related compression of adjacent structures, potentially causing conditions such as superior vena cava syndrome or airway obstruction. The clinical presentation depends on the aggressiveness of the lymphoma subtype-aggressive forms usually exhibit fast-growing tumors, whereas indolent variants may have a slower progression, often presenting with intermittent or progressive lymph node swelling.

Request for a detailed insights report on Diffuse Large B-Cell Lymphoma pipeline insights [https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

"Diffuse Large B-Cell Lymphoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Diffuse Large B-Cell Lymphoma Therapeutics Market.

Key Takeaways from the Diffuse Large B-Cell Lymphoma Pipeline Report

*
DelveInsight's Diffuse Large B-Cell Lymphoma pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Diffuse Large B-Cell Lymphoma treatment.

*
In April 2024, Rituxan (rituximab) was approved for the treatment of various blood cancers, autoimmune disorders, and inflammatory conditions, such as follicular lymphoma (FL), non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), mature B-cell acute leukemia (B-AL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and pemphigus vulgaris (PV). Additionally, RITUXAN HYCELA, a formulation combining rituximab with Halozyme's hyaluronidase human ENHANZE technology, was approved for adults with previously untreated or relapsed/refractory FL, untreated DLBCL, and both untreated and treated CLL.

*
In March 2024, Lantern Pharma began dosing two participants in a Phase Ia/Ib clinical trial for LP-284, an experimental drug for relapsed or refractory NHL. LP-284 is an innovative small molecule designed to target and eliminate cancer cells with mutations in DNA damage repair pathways through a synthetically lethal approach.

*
In May 2023, Bristol Myers Squibb reported positive topline results from two studies: TRANSCEND FL, a global Phase 2, open-label, multicenter, single-arm trial of Breyanzi (lisocabtagene maraleucel) in patients with relapsed or refractory follicular lymphoma (FL), and TRANSCEND NHL 001, a pivotal Phase 1, open-label, multicenter, single-arm study of Breyanzi in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), including mantle cell lymphoma (MCL). Both studies met their primary endpoint of overall response rate, with Breyanzi demonstrating statistically significant and clinically meaningful responses in relapsed or refractory FL and MCL.

*
In May 2023, Janssen Biotech, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced a global collaboration and licensing agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies.

*
In May 2023, Genmab A/S revealed that the U.S. Food and Drug Administration (FDA) approved EPKINLY Trademark (epcoritamab-bysp), the first and only T-cell engaging bispecific antibody for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma and high-grade B-cell lymphoma, following two or more lines of systemic therapy.

*
In January 2023, Fate Therapeutics, Inc. announced it had rejected a proposal from Janssen Biotech, Inc. to continue their collaboration and option agreement under new terms. As a result, the agreement was terminated, and all collaboration activities were scheduled to wind down by the first quarter of 2023.

*
Key Diffuse Large B-Cell Lymphoma companies such asMiltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, and others are evaluating new drugs for Diffuse Large B-Cell Lymphoma to improve the treatment landscape.

*
Promising Diffuse Large B-Cell Lymphoma pipeline therapies in various stages of development include Brentuximab vedotin, Abexinostat, RNK05047, BMF-219, ADI-001, THOR-707, and others.

Diffuse Large B-Cell Lymphoma Pipeline Analysis

The report provides insights into:

*
The report provides detailed insights into the key companies that are developing therapies in the Diffuse Large B-Cell Lymphoma Market.

*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diffuse Large B-Cell Lymphoma treatment.

*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Diffuse Large B-Cell Lymphoma market.

Download our free sample page report on Diffuse Large B-Cell Lymphoma pipeline insights [https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Diffuse Large B-Cell Lymphoma Emerging Drugs

*
Brentuximab vedotin: Pfizer

*
Abexinostat: Xynomic Pharmaceuticals

*
RNK05047: Ranok Therapeutics

*
BMF-219: Biomea Fusion

*
ADI-001: Adicet Bio

*
THOR-707: Sanofi

Diffuse Large B-Cell Lymphoma Companies

More than 70 prominent companies are actively developing treatments for Diffuse Large B-Cell Lymphoma (DLBCL). Of these, Pfizer stands out with drug candidates that have reached the most advanced stage of development-Phase III clinical trials.

DelveInsight's report covers around 75+ products under different phases of clinical development like

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I) along with the details of

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Diffuse Large B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Diffuse Large B-Cell Lymphoma Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Diffuse Large B-Cell Lymphoma Therapies and Key Companies: Diffuse Large B-Cell Lymphoma Clinical Trials and advancements [https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Diffuse Large B-Cell Lymphoma Pipeline Therapeutic Assessment

- Diffuse Large B-Cell Lymphoma Assessment by Product Type

- Diffuse Large B-Cell Lymphoma By Stage

- Diffuse Large B-Cell Lymphoma Assessment by Route of Administration

- Diffuse Large B-Cell Lymphoma Assessment by Molecule Type

Download Diffuse Large B-Cell Lymphoma Sample report to know in detail about the Diffuse Large B-Cell Lymphoma treatment market @ Diffuse Large B-Cell Lymphoma Therapeutic Assessment [https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Diffuse Large B-Cell Lymphoma Current Treatment Patterns

4. Diffuse Large B-Cell Lymphoma - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Diffuse Large B-Cell Lymphoma Late-Stage Products (Phase-III)

7. Diffuse Large B-Cell Lymphoma Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Diffuse Large B-Cell Lymphoma Discontinued Products

13. Diffuse Large B-Cell Lymphoma Product Profiles

14. Diffuse Large B-Cell Lymphoma Key Companies

15. Diffuse Large B-Cell Lymphoma Key Products

16. Dormant and Discontinued Products

17. Diffuse Large B-Cell Lymphoma Unmet Needs

18. Diffuse Large B-Cell Lymphoma Future Perspectives

19. Diffuse Large B-Cell Lymphoma Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Diffuse Large B-Cell Lymphoma Pipeline Reports Offerings [https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=diffuse-large-bcell-lymphoma-clinical-trails-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-miltenyi-biomedicine-adicet-bio-velosbio-novartis-pharmaceu]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.